Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis.

IF 2 Q2 ECONOMICS
Zheng-Yi Zhou, Mark E Bensink, Nisha C Hazra, Chunyi Xu, Bruce Hendry, Claire C Sharpe, Mo Zhou
{"title":"Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis.","authors":"Zheng-Yi Zhou, Mark E Bensink, Nisha C Hazra, Chunyi Xu, Bruce Hendry, Claire C Sharpe, Mo Zhou","doi":"10.1007/s41669-024-00527-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a UK societal perspective.</p><p><strong>Methods: </strong>We used the time trade-off (TTO) method to derive utility values for various health states in IgAN, defined based on chronic kidney disease (CKD) stage, proteinuria, dialysis, and nephrotic syndrome (CKD stages 1-4, proteinuria < 1 g/day vs ≥ 1 g/day; CKD stage 5, dialysis vs non-dialysis). We developed health state vignettes to describe typical symptoms and quality-of-life impairments of IgAN. Eligible participants from the UK general public completed a computer-assisted telephone interview. Estimated TTO utility values were reviewed against visual analogue scale (VAS)-derived values.</p><p><strong>Results: </strong>In total, 200 participants were included in the study (mean age, 48.9 years; female, 59.0%). Mean (standard deviation [SD]) utility values were 0.84 (0.17) and 0.71 (0.23) for CKD stage 1/2 with proteinuria < 1 g/day and with proteinuria ≥ 1 g/day, respectively; 0.68 (0.23) and 0.61 (0.25) for CKD stage 3; and 0.55 (0.26) and 0.49 (0.27) for CKD stage 4. Mean (SD) utility of CKD stage 5 with and without dialysis was 0.38 (0.30) and 0.42 (0.28), respectively. The mean (SD) utility value of nephrotic syndrome was 0.43 (0.33).</p><p><strong>Conclusions: </strong>Our results indicated that various IgAN health states are associated with impaired health status, with substantial utility decrements related to disease progression, elevated proteinuria, and nephrotic syndrome.</p>","PeriodicalId":19770,"journal":{"name":"PharmacoEconomics Open","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s41669-024-00527-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immunoglobulin A nephropathy (IgAN) is a rare progressive disease that can lead to kidney failure. The current study aimed to estimate health state utility values for IgAN from a UK societal perspective.

Methods: We used the time trade-off (TTO) method to derive utility values for various health states in IgAN, defined based on chronic kidney disease (CKD) stage, proteinuria, dialysis, and nephrotic syndrome (CKD stages 1-4, proteinuria < 1 g/day vs ≥ 1 g/day; CKD stage 5, dialysis vs non-dialysis). We developed health state vignettes to describe typical symptoms and quality-of-life impairments of IgAN. Eligible participants from the UK general public completed a computer-assisted telephone interview. Estimated TTO utility values were reviewed against visual analogue scale (VAS)-derived values.

Results: In total, 200 participants were included in the study (mean age, 48.9 years; female, 59.0%). Mean (standard deviation [SD]) utility values were 0.84 (0.17) and 0.71 (0.23) for CKD stage 1/2 with proteinuria < 1 g/day and with proteinuria ≥ 1 g/day, respectively; 0.68 (0.23) and 0.61 (0.25) for CKD stage 3; and 0.55 (0.26) and 0.49 (0.27) for CKD stage 4. Mean (SD) utility of CKD stage 5 with and without dialysis was 0.38 (0.30) and 0.42 (0.28), respectively. The mean (SD) utility value of nephrotic syndrome was 0.43 (0.33).

Conclusions: Our results indicated that various IgAN health states are associated with impaired health status, with substantial utility decrements related to disease progression, elevated proteinuria, and nephrotic syndrome.

估算免疫球蛋白 A 肾病的健康状态效用值:时间权衡分析
背景:免疫球蛋白 A 肾病(IgAN免疫球蛋白 A 肾病(IgAN)是一种罕见的进展性疾病,可导致肾衰竭。本研究旨在从英国社会的角度估算 IgAN 的健康状态效用值:我们使用时间权衡(TTO)法得出了 IgAN 患者各种健康状态的效用值,这些健康状态是根据慢性肾脏病(CKD)分期、蛋白尿、透析和肾病综合征(CKD 1-4 期,蛋白尿 < 1 克/天 vs ≥ 1 克/天;CKD 5 期,透析 vs 非透析)定义的。我们编写了健康状况小故事来描述 IgAN 的典型症状和生活质量障碍。英国公众中符合条件的参与者完成了计算机辅助电话访谈。根据视觉模拟量表(VAS)得出的数值对估计的TTO效用值进行审查:共有 200 名参与者参与了研究(平均年龄 48.9 岁;女性占 59.0%)。蛋白尿<1克/天的CKD 1/2期和蛋白尿≥1克/天的CKD 1/2期效用值平均值(标准差[SD])分别为0.84(0.17)和0.71(0.23);CKD 3期效用值分别为0.68(0.23)和0.61(0.25);CKD 4期效用值分别为0.55(0.26)和0.49(0.27)。有透析和无透析的 CKD 第 5 阶段的平均(标清)效用值分别为 0.38 (0.30) 和 0.42 (0.28)。肾病综合征的平均(标清)效用值为 0.43 (0.33):我们的研究结果表明,IgAN的各种健康状态都与健康状况受损有关,疾病进展、蛋白尿升高和肾病综合征会导致效用大幅下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
64
审稿时长
8 weeks
期刊介绍: PharmacoEconomics - Open focuses on applied research on the economic implications and health outcomes associated with drugs, devices and other healthcare interventions. The journal includes, but is not limited to, the following research areas:Economic analysis of healthcare interventionsHealth outcomes researchCost-of-illness studiesQuality-of-life studiesAdditional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in PharmacoEconomics -Open may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信